Renal Cell Carcinoma Therapy Devices Market

Renal cell carcinoma (RCC) is increasing in incidence and one third of newly diagnosed cases already are metastatic. The metastatic spread of solid tumors renders RCC incurable by surgical resection and consequently more difficult to treat. New molecular-targeted therapies have played a pivotal role in RCC treatment.

Renal Cell Carcinoma Therapy Devices Market contains market size and forecasts of Renal Cell Carcinoma Therapy Devices in Global, including the following market information:

Global Renal Cell Carcinoma Therapy Devices Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Renal Cell Carcinoma Therapy Devices market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Directed Energy-based Therapy Devices Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Renal Cell Carcinoma Therapy Devices include AngioDynamics, Inc., Boston Scientific Corporation (Galil Medical, Inc.), IceCure Medical, HealthTronics, Inc., HistoSonics, Inc., Integra LifeSciences Holdings Corporation, Medtronic plc, Monteris Medical, Inc. and Novocure GmbH and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Renal Cell Carcinoma Therapy Devices companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Renal Cell Carcinoma Therapy Devices Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, by Type, 2021 (%)

Directed Energy-based Therapy Devices

Drug/Fluid Delivery and Infusion Therapy Devices

Global Renal Cell Carcinoma Therapy Devices Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Global Renal Cell Carcinoma Therapy Devices Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Renal Cell Carcinoma Therapy Devices revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Renal Cell Carcinoma Therapy Devices revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AngioDynamics, Inc.

Boston Scientific Corporation (Galil Medical, Inc.)

IceCure Medical

HealthTronics, Inc.

HistoSonics, Inc.

Integra LifeSciences Holdings Corporation

Medtronic plc

Monteris Medical, Inc.

Novocure GmbH

Varian Medical Systems, Inc.